Publications [#381259] of Seog Oh

Papers Published

1. Gerds, AT; Gotlib, J; Bose, P; Deininger, MW; Dunbar, A; Elshoury, A; George, TI; Gojo, I; Gundabolu, K; Hexner, E; Hobbs, G; Jain, T; Jamieson, C; Kuykendall, AT; McMahon, B; Mohan, SR; Oehler, V; Oh, S; Pardanani, A; Podoltsev, N; Ranheim, E; Rein, L; Salit, R; Snyder, DS; Stein, BL; Talpaz, M; Thota, S; Vachhani, P; Wadleigh, M; Walsh, K; Ward, DC; Bergman, MA; Sundar, H, Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology., J Natl Compr Canc Netw, vol. 18 no. 9 (September, 2020), pp. 1248-1269 [doi]
   (last updated on 2026/01/20)

   Abstract:
   Eosinophilic disorders and related syndromes represent a heterogeneous group of neoplastic and nonneoplastic conditions, characterized by more eosinophils in the peripheral blood, and may involve eosinophil-induced organ damage. In the WHO classification of myeloid and lymphoid neoplasms, eosinophilic disorders characterized by dysregulated tyrosine kinase (TK) fusion genes are recognized as a new category termed, myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB or FGFR1 or with PCM1-JAK2. In addition to these aforementioned TK fusion genes, rearrangements involving FLT3 and ABL1 genes have also been described. These new NCCN Guidelines include recommendations for the diagnosis, staging, and treatment of any one of the myeloid/lymphoid neoplasms with eosinophilia (MLN-Eo) and a TK fusion gene included in the 2017 WHO Classification, as well as MLN-Eo and a FLT3 or ABL1 rearrangement.